arXiv (All)
open access
Targeted Data Fusion for Region-Specific Survival Effects in the AMP HIV Prevention Trials
The Antibody Mediated Prevention (AMP) trials opened a new scientific frontier by showing that passively administered monoclonal broadly neutralizing antibodies (bnAbs) could prevent HIV-1 acquisition. The trials enrolled 4,611 participants across four epidemiologically distinct regions, with 174 HI
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV#1246843
- Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults#184912
- ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer#1261056
- Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma#873871
- The impact of immune dysregulation on the risk of malignancy in common variable immunodeficiency: insights from a multicenter study#448446
Record · ID 1326090
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive